fosfomycin + tobramycin

Fosfomycin + tobramycin is a fixed-dose combination of two antibiotics, **fosfomycin** (a phosphonic acid antibiotic) and **tobramycin** (an aminoglycoside), typically formulated in a 4:1 weight ratio for inhalation therapy, primarily targeting **Pseudomonas aeruginosa** infections in patients with cystic fibrosis[2][5][7]. Fosfomycin inhibits bacterial cell wall synthesis by targeting UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), while tobramycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination demonstrates **synergistic and bactericidal activity**, with fosfomycin also enhancing the active uptake of tobramycin in bacteria, leading to increased inhibition of protein synthesis, improved bacterial killing, and a reduced frequency of resistance development[1][2][3][5]. The combination has been evaluated primarily for **inhalation** use in cystic fibrosis, and is investigated as a potentially safer and more effective antibacterial regimen for chronic airway infections in this population[2][5].

Brand names

FTI

Other names

fosfomycin/tobramycinfosfomycin-tobramycin